[Use of monoclonal antibodies in the treatment of cancer of the pancreas: towards new progress?].
Pancreatic cancers rank amongst the most deadly malignant diseases with a 5 year-survival percentage less than 2% and few therapeutic approaches are hitherto available. This study presents the recent attempts to construct antibodies for therapy. The characterization of pancreatic tumor-associated antigens which might serve as target antigens for antibody therapy is the limiting factor before considering the treatment of pancreatic cancer with antibodies. Antigens such as CA 19-9, BW 494 and DU-PAN-2 have been reported to be associated with pancreatic cancers. However, monoclonal antibodies directed to these antigens was not proven to be specific enough to warrant therapeutic utilization and new tumor-associated antigens must be identified. Remarkable progress has been made recently in the construction of antibodies for therapy. Amongst these antibodies are "chimeric" antibodies, antibody heteroconjugates or hybrid antibodies. The in vivo utilization of those antibodies may well result in effective tumor-cell destruction.
Département de biologie clinique, Institut Gustave-Roussy, Villejuif, France.
D
D
Bellet
J M
JM
Bidart
P
P
Rougier
C
C
Bohuon
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000032:analysis; D005818:Genetic Engineering / Q000639:trends; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm
L'utilisation d'anticorps monoclonaux pour le traitement des cancers du pancréas: vers de nouveaux progrès?